Business
Assembly Bio Announces October Conference Participation
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), announced participation in the below upcoming conferences focused on HBV: The Science of HBV Cure Meeting 2021 ONLINEPresenter: William Delaney, PhD, Chief Scientific Officer Date/Time: Tuesday, October 12 at 7:30 a.m. ET (7:30 p.m. SGT)Session: Capsid Inhibitors Title: Discovery and Development of Novel Inhibitors of HBV Core Protein for the Treatment for Chronic Hepatitis B H.C. Wainwright 2nd Annual Hepatitis B (HBV) Conference (virtual)Presenter: John McHutchison, AO, MD, Chief Executive Officer and PresidentDate/Time: Wednesday, October 13 at 2:00 p.m. ETWebcast: Fireside chat live stream and replay will be available in the Events & Presentations section of the Company’s website at www.assemblybio.com. About Assembly BiosciencesAssembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. For more information, visit assemblybio.com. Forward-Looking StatementsThe information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to initiate and complete clinical studies involving its HBV therapeutic product candidates, including studies contemplated by Assembly Bio’s clinical collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidate...